Texas is deep in the heart of Corporate America.  The state is at the top of nearly every credible best states to do business list and our investment attraction and job creation numbers are the envy of economic development professionals across the country.  The Texas economy has no equal and the TexasOne program has played a key role in the state’s ascent to the top.  The Program’s unique marketing approach has boosted the state’s economic development initiative and created global awareness of Texas’ business friendly climate.  The TexasOne program is a public-private partnership of the Texas Economic Development Corporation that markets the state in a dynamic and competitive manner.  Texas’ economic development and marketing successes are a direct result of the financial contributions, collaborative input, and innovative vision of TexasOne members.  Through trade and industry events, business recruitment missions, signature events, advertising, and public relations, as well as an interactive web presence, TexasOne members share a simple message “Texas is wide open for business”.  With the right approach, the right blueprint for success, key players and the full support of the Governor, we can achieve a stronger and more successful campaign in the history of economic development.

Texas Wide Open for Business

Kyowa Kirin, engages in the manufacture and sale of medical products and pharmaceuticals in the therapeutic areas of nephrology, oncology, and immunology in Japan. Its pharmaceutical products include GRAN, a protein that enables a quick recovery from neutropenia and reduces the risk of infection; NESP, an agent for correcting anemia; ESPO, a glycoprotein, which acts as an anemia-relieving treatment for dialysis patients; and CONIEL, a calcium antagonist agent for hypertension and angina pectoris. The company's pharmaceutical products also comprise REGPARA an agent for the treatment of secondary hyperparathyroidism; ALLELOCK/Patanol, which are used as medicine for patients with various types of allergies; and DEPAKENE/TOPINA, antiepileptic agents. It also offers a range of products, including amino acids, nucleic acids, vitamins, and sugars, which are used to produce pharmaceuticals, health foods, foods, cosmetics, and other products; plant growth regulators, feed additives, companion animal-related products, and aquaculture medicinal products; and various types of alcohol for use in alcoholic beverages. In addition, the company manufactures and sells industrial alcohols and solvents for automotive, electronics, and housing industries; performance materials that enable the production of raw materials for lubricants, higher alcohols, and polymeric materials used in various consumer goods; and a range of electronic materials for the information technology industry. Further, it provides seasonings, sweeteners, freeze-dried products, and bakery products and ingredients. The company was founded in 1885 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Kyowa Kirin

Targazyme

Targazyme, Inc. (formerly America Stem Cell, Inc.) is a clinical-stage biopharmaceutical company developing and commercializing breakthrough products designed to improve outcomes for patients receiving cell therapy.  Our most advanced product, TZ101, improves the therapeutic potential of cells by enhancing migration to selective sites in the body and improving retention in tissue. This will increase the effectiveness of the cells in numerous disease indications.  Target indications for the Company’s products include cancer, ischemic diseases like heart failure, critical limb ischemia and diabetic retinopathy, and radiation sickness, each of which represents a large market with significant opportunity to improve outcomes for patients.  The company was founded in 2005 and has received funding from angel investors, the management team, and several non-profit and governmental institutions.

Targazyme develops cancer immunotherapies based on its proprietary cell efficacy multiplier technology. The company’s therapeutics are designed to enhance the delivery and potency of immune cells to the tumor site, thereby increasing the chances of eliminating, curing, and preventing cancer. Targazyme mainly develops its therapeutics using stem cells and cells engineered using naturally occurring enzymes, but its technology can be applied to natural killer (NK) cells, T-cells, Mesenchymal stem cells (MCS), regulatory T cells, and others. Targazyme’s therapeutics are applicable to various types of diseases, such as melanoma, leukemia, lymphoma, solid tumors, breast cancer, lung cancer, colon cancer, and auto-immune diseases.

Novel therapies to reboot cells and organs

Cell & Gene Therapy

Targazyme Appoints Jim Caggiano as CEO

Targazyme develops cancer immunotherapies based on its proprietary cell efficacy multiplier technology. The company’s therapeutics are designed to enhance the delivery and potency of immune cells to the tumor site, thereby increasing the chances of eliminating, curing, and preventing cancer. Targazyme mainly develops its therapeutics using stem cells and cells engineered using naturally occurring enzymes, but its technology can be applied to natural killer (NK) cells, T-cells, Mesenchymal stem cells (MCS), regulatory T cells, and others. Targazyme’s therapeutics are applicable to various types of diseases, such as melanoma, leukemia, lymphoma, solid tumors, breast cancer, lung cancer, colon cancer, and auto-immune diseases.As of May 2024, Targazyme’s clinical pipeline included its therapeutic stem cell candidate for treating various types of cancers, TZ 101. The company was developing multiple applications for TZ 101, testing its efficacy for treating patients with blood cancer, auto-immnue diseases, and a T-cell variant of the candidate for blood cancer patients. The trials for the various applications of TZ 101 were in Phase II, Phase I, and Phase I, respectively. Additionally, the company was developing therapeutics for cancer immunotherapy via the company’s Fucosylation Platform Technology (FucoTIL) platform for treating cancer in the lungs, breast, and colon. All applications were in preclinical stages, with the expectation of them entering clinical testing in 2023. Key customers and partnershipsAs of May 2024, the company noted that it had partnered with several cancer centers, including MD Anderson Cancer Center, Harvard, University of Pennsylvania Medical Center, and Yale Medical Center. Additionally, it had secured corporate partnerships with entities such as Kyowa Hakko Kirin, VidaCord of Spain, ThermoFisher, AVID Bioscience, Aragen, George Clinical, and NIH/NCI.

<div>
 
 Tenaya Therapeutics is a developer of therapeutics for heart disease. The company develops its therapeutics using precision medicine, gene therapy, and cellular regeneration. Tenaya produces therapeutics that also use proprietary in-vivo and in-vitro models. Additionally, the company has developed in-house adeno-associated virus (AAV) capsid engineering capabilities and has screened over one billion variants from more than 30 diverse, proprietary AAV libraries. The company is publicly listed on the Nasdaq and trades under the ticker symbol TNYA.&nbsp;&nbsp;
 
 
 In October 2023 Tenaya Therapeutics (Tenaya) received FDA clearance for the company&rsquo;s investigational new drug application (TN-401) to initiate clinical testing. TN-401 is Tenaya&rsquo;s adeno-associated virus serotype 9-based investigational gene therapy drug candidate for the treatment of arrhythmogenic right ventricular cardiomyopathy caused by mutations in the plakophilin-2 gene. 
 
 
 As of May 2024, the company&rsquo;s clinical pipeline included two candidates in Phase I clinical trials, a gene therapeutic for the treatment of Hypertrophic Cardiomyopathy, and a small molecule inhibitor for the treatment of heart failure with preserved ejection fraction. Additionally, Tenaya had one gene therapy candidate and two genetic medicine candidates in preclinical testing phases, along with five genetic medicine candidates in the discovery stage. 
 
 
 
</div>

Tenaya Therapeutics

<div>
 
 Sarepta Therapeutics is a gene therapy provider for conditions such as Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy 
 (LGMD), and Charcot-Marie-Tooth Disease. The company&rsquo;s therapeutics incorporate technology related to gene therapy, RNA technologies, and gene editing. The company leverages a proprietary phosphorodiamidate morpholino oligomer (PMO) platform for the development of its RNA-based therapeutics. As of August 2023, the company had four FDA-approved treatments for DMD: ELEVIDYS, EXONDYS 51, VYONDYS 53, and AMONDYS 45. Sarepta Therapeutics is also listed on the Nasdaq, trading under the symbol SRPT.&nbsp;&nbsp;&nbsp;&nbsp;
 
 
 
 
 As of May 2024, the company had several RNA, gene, and gene editing therapeutics in various clinical stages. Sarepta had two RNA therapeutics, both for the treatment of DMD, one in clinical testing, and the other in pre-clinical testing. Additionally, the company had six gene therapeutics, one for the treatment of DMD (both in clinical testing), four for the treatment of LGMD (three in clinical testing, one in preclinical testing) and one for multiple targets (in preclinical testing). Also, Sarepta had two gene editing-based therapeutics in development for the treatment of DMD, both in preclinical testing phases. 
 
 
 
 
 Key customers and partnerships
 
 
 
 
 Over the years since its founding, Sarepta has partnered with several industry and academic partners. The list includes Dyno Therapeutics, Genethon, Genevant Sciences, Hansa Biopharma, Roche, Columbia University, Harvard University, Translational Laboratory of Murdoch University, University of Florida College of Medicine, The Abigail Wexner Research Institute at Nationwide Children&rsquo;s Hospital, University of Massachusetts Medical School, and the University of Western Australia.&nbsp;&nbsp;
 
 
 
 
 In October 2021, Sarepta and healthcare giant Roche announced they would collaborate on carrying out a clinical study of Sarepta&rsquo;s therapeutic candidate SRP-9001 for the treatment of DMD.&nbsp;
 
 
 
 
 Sarepta and pharmaceutical company Catalent announced that in January 2023, the companies were signing a commercial supply agreement. Through the agreement,&nbsp; Catalent would manufacture Sarepta&rsquo;s gene therapeutic for the treatment of DMD; delandistrogene moxeparvovec (SRP-9001).
 
 
 
</div>

Sarepta Therapeutics

<div>
 
 Mesoblast is a cell therapy manufacturer that provides therapeutics for oncology, cardiovascular, orthopedic, hematology, immunity, and inflammation-related conditions. The company is listed on the Australian Stock Exchange and trades under the ticker symbol &ldquo;MSB.&rdquo; Mesoblast develops therapeutics using its proprietary mesenchymal lineage cell technology platform, which is used to produce cryopreserved, off-the-shelf, and cellular-based solutions. The company also incorporates 3D bioreactor technology and automation into its production process to produce higher yields.&nbsp;
 
 
 
 
 As of May 2024, the company had five candidates that are in various stages of clinical testing. Mesoblast&rsquo;s steroid-refractory candidate for Acute Graft Versus Host Disease is currently in late-stage Phase III clinical testing and is the closest candidate to commercialization. The company&rsquo;s drug candidates for acute respiratory distress syndrome, chronic low back pain, and chronic heart failure and reduced ejection fraction are also in Phase III clinical testing while its candidate for inflammatory bowel disease is in Phase II of clinical testing.&nbsp;
 
 
 
 
 Key customers and partnerships
 
 
 
 
 The company has secured several agreements with international companies with regard to development and commercialization of Mesoblast&rsquo;s candidates, including Gr&uuml;nenthal GmBH, JCR Pharmaceuticals, Tasly Pharmaceutical Group, TiGenix NV, and the Lonza Group.&nbsp;
 
 
 
 
 Additionally, in April 2020, Mesoblast partnered with The US NIH&rsquo;s National Heart, Lung, and Blood Institute to conduct testing of its allogeneic mesenchymal stem cell (MSC) product candidate, &ldquo;remestemcel-L.&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;
 
 
 
 
 
</div>

Mesoblast

<div>
 
 Ocugen is a gene therapy manufacturer that develops vaccine, cell, and gene-based therapeutics for infectious, eye, and orthopedic diseases. Its cell therapy includes a three dimensional tissue-engineered cartilage disk through the growth of chondrocytes &ndash; the cells responsible for maintaining cartilage health. Its gene therapy solution consists of creating a copy of the patient&rsquo;s gene in order to replace mutated/damaged genes. The company is publicly listed on the Nasdaq, and trades under the symbol &lsquo;OCGN&rsquo;.&nbsp;
 
 
 As of May 2024, the company had five therapeutic solutions being clinically tested. The company was developing four gene therapies for the treatment of retinitis pigmentosa, Leber congenital amaurosis, geographic atrophy, and orphan disease. Its treatment candidate for retinitis pigmentosa was in Phase III of clinical study, while its other gene therapies were in Phase I/II. 
 Ocugen was also developing a biological material, in the IND stage, for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration. The company's cell therapy for the treatment of articular cartilage defects in the knee was in Phase III of clinical study. Finally, the company was also developing three vaccines, all in IND stages, for prevention of diseases caused by the flu, Covid-19, and a combination of the flu and Covid-19.
 
 
 Key customers and partnerships
 
 
 Ocugen partnered with biopharmaceutical manufacturer Jubilant HollisterStier of Spokane in June 2021 to manufacture its Covid-19 therapeutic COVAXIN. Through the partnership, Jubilant would be the potential commercial manufacturer of Ocugen&rsquo;s vaccine for the US and Canadian markets.
 
 
 
 
 
</div>

Ocugen

<div>
 
 MeiraGTx is a developer of gene therapies that aim to treat ocular diseases and problems, neurodegenerative disorders, and salivary gland and autoimmune disorders. MeriaGTx is also developing riboswitch-inducible expression programs for the treatment of inherited obesity and Wilson disease, along with producing small-molecule riboswitch inducers. The company is listed on the Nasdaq and trades under the symbol MGTX.&nbsp;&nbsp;
 
 
 As of May 2024, the company had four gene-based therapeutic candidates in Phase II of their clinical trials for the treatment of (1) xerostomia, Parkinson's Disease, and RPE65-Associated retinal dystrophy and (2) achromatopsia. The company also had one therapeutic being developed to treat Sjogren&rsquo;s Syndrome that was in Phase I/II of its clinical trials. Additionally, MeiraGTx had seven other therapeutics in discovery/preclinical stages. The company was also developing a therapeutic for X-linked retinitis pigmentosa in collaboration with Janssen, which was in Phase III of clinical trials. 
 
 
 Key customers and partnerships
 
 
 MeiraGTx partnered with the International Institute of Risk and Safety Management (IIRSM) in November 2022 to influence risk agendas, raise awareness, the standards of risk, and safety management across the industry.&nbsp;
 
 
 Funding and financials
 
 
 Meira last raised funds in October 2023, when the company secured a strategic investment of USD 30 million from Sanofi. As part of the transaction, Sanofi was granted the right of first negotiation for MeiraGTx's gene regulation technology in certain targets.&nbsp;
 
 
 
</div>

MeiraGTx

Companies producing cells, genes, tissues, and biomaterials such as exosomes and extracellular matrix for drug developers and pharmaceutical companies developing regenerative medicine

Chimeric antigen receptor T-cell (CAR-T) therapy involves genetically engineering T cells to target and kill cancer cells

Companies conducting R&D on therapies that modify or introduce new genes into the body to treat diseases

Includes therapies that use cells (other than CAR-T and stem cells) such as Adipose-Derived Regenerative Cells (ADRCs), cardiosphere-derived cells, and gamma delta T cells (GDT cells)

Stem cell therapy involves using stem cells usually extracted from the bone marrow and umbilical cord blood to repair a variety of diseases

Startups in the hub consider individual patient profiles, involving variability in genes, environment, and lifestyle

Genomics helps understand the genetic information stored in the DNA to develop targeted treatments

Targazyme

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless